Besides, the risk scores of the signature were applied to predict prognosis in GC patients and median risk score was utilized to classify patients into the high- or low-risk groups, which was calculated as follows: risk score = (−0.181) × expression of SP1 + (−0.085) × expression of MYB + (−0.076) × expression of ALDH3A2 + (−0.075) × expression of KEAP1 + (−0.031) × expression of AIFM2 + (−0.026) × expression of ITGB4 + (0.072) × expression of TGFBR1 + (0.138) × expression of MAP1LC3B + (0.148) × expression of NOX4 + (0.345) × expression of ZFP36. This evidence concerns the gene MAP1LC3B and gastric cancer.